Drug intelligence / Profile preview

LY900021

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**LY900021** was an investigational subcutaneous formulation of **mirikizumab** developed by Eli Lilly. It combined mirikizumab, a humanized IgG4 monoclonal antibody against the p19 subunit of interleukin-23, with LY9999QS, a permeation enhancer intended to improve the tolerability and administration of larger-volume subcutaneous injections. The formulation was evaluated in completed Phase 1 healthy-volunteer studies and has not been established as a marketed product.

Other names: LY 900021LY900021LY-900021LY9999QS + mirikizumab

Targets

IL23A (Interleukin-23 p19 Subunit)

Beyond the preview

Go deeper on LY900021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY900021.

Explore the full profile